Department of Surgery, Vascular and Endovascular Surgery Unit, Usl Toscana Centro, "San Giovanni di Dio" Hospital, Florence, Italy.
Division of Vascular Surgery, University at Buffalo, State University of New York, NY, USA.
Eur J Vasc Endovasc Surg. 2018 Jul;56(1):40-47. doi: 10.1016/j.ejvs.2018.03.006. Epub 2018 Apr 17.
The aim of this study was to define the safety and effectiveness of a contrast enhanced ultrasound (CEUS) based follow up for endovascular aortic repair (EVAR) surveillance at a mid-term period (4 years).
At the tertiary referral centre EVAR surveillance was based on plain abdominal radiograph and duplex ultrasound (CDU), with computed tomography angiography (CTA) reserved for any non-diagnostic imaging during the period 1999-2011 (Group A). From 2012, CEUS was performed when (a) any endoleak was detected at CDU, (b) sac growth > 5 mm within 6 months, and routinely for (c) patients with renal insufficiency (above Stage 3 chronic kidney disease), or (d) iodine contrast allergy (Group B).
A total of 880 patients (mean age 75.6 ± 8.4 years; 824 male) who underwent EVAR between 1999 and 2015 and with a minimum of 1 year follow up were included. Six hundred and nineteen patients were in Group A (70%) and the remaining 261 in Group B (30%). Median follow up was 48 months (interquartile range 24-84). During the study period 318 CEUS scans were performed with no related complications. Indications for CEUS were the following: (a) 160 (50%) endoleak presence, (b) 34 (11%) significant sac expansions, (c) 91 (29%) renal insufficiency (Stage 3 or above CKD), and 33 (10%) iodine contrast allergies. CEUS was compared with CTA, with additional confirmation by angiographic and operative findings in the case of repair in the first 100 patients. CEUS had 100% sensitivity and 100% specificity in classifying endoleaks. No differences in endoleak, re-interventions and sac shrinkage percentage were seen between the two groups at 4 years. A 4 year analysis of CTA use found a 90% reduction with the introduction of CEUS.
The introduction of a CEUS based protocol for EVAR follow up was safe and effective and it was similar to the previous CTA based follow up protocol with regard to identification of endoleaks in a mid-term period. Moreover, CEUS allowed for 90% reduction of CTA, thereby decreasing radiation exposure for patients.
本研究旨在定义对比增强超声(CEUS)在中期(4 年)随访中用于血管内修复(EVAR)监测的安全性和有效性。
在三级转诊中心,EVAR 监测基于腹部平片和双功超声(CDU),计算机断层血管造影(CTA)仅保留在 1999 年至 2011 年期间任何非诊断性成像期间(A 组)。从 2012 年开始,当(a)在 CDU 检测到任何内漏时,(b)6 个月内囊腔生长>5mm,以及(c)肾功能不全(CKD 3 期以上)或(d)碘对比过敏(B 组)时,进行 CEUS。
共纳入 1999 年至 2015 年间接受 EVAR 治疗且随访至少 1 年的 880 例患者(平均年龄 75.6±8.4 岁,824 例男性)。619 例患者在 A 组(70%),其余 261 例在 B 组(30%)。中位随访时间为 48 个月(四分位距 24-84)。研究期间共进行了 318 次 CEUS 扫描,无相关并发症。CEUS 的适应证如下:(a)160 例(50%)存在内漏,(b)34 例(11%)明显囊腔扩张,(c)91 例(29%)肾功能不全(CKD 3 期或以上),33 例(10%)碘对比过敏。CEUS 与 CTA 进行比较,在前 100 例患者中,通过血管造影和手术结果进行了额外的确认。CEUS 在分类内漏方面具有 100%的敏感性和 100%的特异性。两组在 4 年内的内漏、再次干预和囊腔缩小百分比均无差异。对 CTA 使用的 4 年分析发现,引入 CEUS 后,CTA 的使用减少了 90%。
引入基于 CEUS 的 EVAR 随访方案是安全有效的,与之前的基于 CTA 的随访方案在中期识别内漏方面相似。此外,CEUS 使 CTA 的使用减少了 90%,从而降低了患者的辐射暴露。